Skip to content

Study · Randomized controlled trial · n = 15 · 2003

1 result

Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders.

Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Aronowitz BR, Mosovich S

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology1 Jan 2003Cited by 441 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with autism or Asperger's disorder, oxytocin infusion significantly reduced repetitive behaviors compared with placebo infusion.

    In plain wordsIn adults with autism or Asperger's disorder, oxytocin infusion reduced repetitive behaviors more than placebo infusion.

    Peptide
    Oxytocin
    Outcome
    DecreaseRepetitive behaviors (primary outcome rating)
    Study

    n = 15

    Comparator
    Placebo infusion
    Analysis
    Primary
    Outcome group
    Autism core symptoms · Mental health and mood
    Studied dose
    Dose not stated · infusionAs given in this study (human).

    Source sentences

    Summary
    Patients with autism spectrum disorders showed a significant reduction in repetitive behaviors following oxytocin infusion in comparison to placebo infusion.
    2 context sentences
    Summary · context
    The primary outcome measure was an instrument rating six repetitive behaviors: need to know, repeating, ordering, need to tell/ask, self-injury, and touching.
    Summary · context
    This study examined the impact of oxytocin on repetitive behaviors in 15 adults with autism or Asperger's disorder via randomized double-blind oxytocin and placebo challenges.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.